Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2016

01-02-2016 | Original Article

Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis

Authors: Georg Kuhnert, Ronald Boellaard, Sergej Sterzer, Deniz Kahraman, Matthias Scheffler, Jürgen Wolf, Markus Dietlein, Alexander Drzezga, Carsten Kobe

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2016

Login to get access

Abstract

Background

In oncological imaging using PET/CT, the standardized uptake value has become the most common parameter used to measure tracer accumulation. The aim of this analysis was to evaluate ultra high definition (UHD) and ordered subset expectation maximization (OSEM) PET/CT reconstructions for their potential impact on quantification.

Patients and methods

We analyzed 40 PET/CT scans of lung cancer patients who had undergone PET/CT. Standardized uptake values corrected for body weight (SUV) and lean body mass (SUL) were determined in the single hottest lesion in the lung and normalized to the liver for UHD and OSEM reconstruction. Quantitative uptake values and their normalized ratios for the two reconstruction settings were compared using the Wilcoxon test. The distribution of quantitative uptake values and their ratios in relation to the reconstruction method used were demonstrated in the form of frequency distribution curves, box-plots and scatter plots. The agreement between OSEM and UHD reconstructions was assessed through Bland-Altman analysis.

Results

A significant difference was observed after OSEM and UHD reconstruction for SUV and SUL data tested (p < 0.0005 in all cases). The mean values of the ratios after OSEM and UHD reconstruction showed equally significant differences (p < 0.0005 in all cases). Bland-Altman analysis showed that the SUV and SUL and their normalized values were, on average, up to 60 % higher after UHD reconstruction as compared to OSEM reconstruction.

Conclusion

OSEM and HD reconstruction brought a significant difference for SUV and SUL, which remained constantly high after normalization to the liver, indicating that standardization of reconstruction and the use of comparable SUV measurements are crucial when using PET/CT.
Literature
1.
go back to reference Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008;112:3989–94.PubMedPubMedCentralCrossRef Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008;112:3989–94.PubMedPubMedCentralCrossRef
2.
go back to reference Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3048–58.PubMedCrossRef Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3048–58.PubMedCrossRef
3.
go back to reference Ito T, Wan CN, Reivich M, Kuhl DE, Casella J, Fowler JS, et al. Labeled 2-deoxy-D-glucose analogs. 18F-labeled 2-deoxy- 2-fluoro-D-glucose, 2-deoxy- 2-fluoro-D-mannose and 14C–2-deoxy- 2-fluoro-D-glucose. J Label Compd Radiopharm. 1978;14:175–83.CrossRef Ito T, Wan CN, Reivich M, Kuhl DE, Casella J, Fowler JS, et al. Labeled 2-deoxy-D-glucose analogs. 18F-labeled 2-deoxy- 2-fluoro-D-glucose, 2-deoxy- 2-fluoro-D-mannose and 14C–2-deoxy- 2-fluoro-D-glucose. J Label Compd Radiopharm. 1978;14:175–83.CrossRef
4.
go back to reference Warburg O, Posener K, Negelein E. Über den Stoffwechsel der Carcinomzelle. Biochem Z. 1924;152:309–35. Warburg O, Posener K, Negelein E. Über den Stoffwechsel der Carcinomzelle. Biochem Z. 1924;152:309–35.
5.
go back to reference Boellaard R, Delgado-Bolten R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.PubMedPubMedCentralCrossRef Boellaard R, Delgado-Bolten R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.PubMedPubMedCentralCrossRef
6.
go back to reference Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–33.PubMedCrossRef Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–33.PubMedCrossRef
7.
go back to reference Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med. 2008;49:1038–46.PubMedPubMedCentralCrossRef Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med. 2008;49:1038–46.PubMedPubMedCentralCrossRef
8.
go back to reference Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S–50.PubMedPubMedCentralCrossRef Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S–50.PubMedPubMedCentralCrossRef
9.
go back to reference Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, et al. Quantitative analysis of response to treatment with erlotinib in advanced non–small cell lung cancer using 18F-FDG and 3’-Deoxy-3’-18F-Fluorothymidine PET. J Nucl Med. 2011;52:1871–7.PubMedCrossRef Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, et al. Quantitative analysis of response to treatment with erlotinib in advanced non–small cell lung cancer using 18F-FDG and 3’-Deoxy-3’-18F-Fluorothymidine PET. J Nucl Med. 2011;52:1871–7.PubMedCrossRef
10.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef
11.
go back to reference Chiaravalloti A, Danieli R, Abbatiello P, Di Pietro B, Travascio L, Cantonetti M, et al. Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1123–32.PubMed Chiaravalloti A, Danieli R, Abbatiello P, Di Pietro B, Travascio L, Cantonetti M, et al. Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1123–32.PubMed
12.
go back to reference Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in national cancer institute trials. J Nucl Med. 2006;47:1059–66.PubMed Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in national cancer institute trials. J Nucl Med. 2006;47:1059–66.PubMed
13.
go back to reference Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR. 2010;195:310–20.PubMedCrossRef Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR. 2010;195:310–20.PubMedCrossRef
14.
go back to reference Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40:985–96.PubMedPubMedCentralCrossRef Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40:985–96.PubMedPubMedCentralCrossRef
15.
go back to reference Rubello D, Gordien P, Morliere C, Guyot M, Bordenave L, Colletti PM, et al. Variability of hepatic 18F-FDG uptake at interim PET in patients with Hodgkin lymphoma. Clin Nucl Med. 2015;40:e405–10. Rubello D, Gordien P, Morliere C, Guyot M, Bordenave L, Colletti PM, et al. Variability of hepatic 18F-FDG uptake at interim PET in patients with Hodgkin lymphoma. Clin Nucl Med. 2015;40:e405–10.
16.
go back to reference Hasenclever D, Kurch L, Mauz-Körholz C, Elsner A, Georgi T, Wallace H, et al. qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1301–8.PubMedCrossRef Hasenclever D, Kurch L, Mauz-Körholz C, Elsner A, Georgi T, Wallace H, et al. qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1301–8.PubMedCrossRef
17.
go back to reference Paquet N, Albert A, Foidart J, Hustinx R. Within-patient Variability of 18F-FDG: standardized uptake values in normal tissues. J Nucl Med. 2004;45:784–8.PubMed Paquet N, Albert A, Foidart J, Hustinx R. Within-patient Variability of 18F-FDG: standardized uptake values in normal tissues. J Nucl Med. 2004;45:784–8.PubMed
18.
go back to reference Keyes Jr JW. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836–9.PubMed Keyes Jr JW. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836–9.PubMed
19.
go back to reference Visser EP, Boerman OC, Oyen WJG. SUV: from silly useless value to smart uptake value. J Nucl Med. 2010;51:173–5.PubMedCrossRef Visser EP, Boerman OC, Oyen WJG. SUV: from silly useless value to smart uptake value. J Nucl Med. 2010;51:173–5.PubMedCrossRef
20.
go back to reference Tylski P, Stute S, Grotus N, Doyeux K, Hapdey S, Gardin I, et al. Comparative assessment of methods for estimating tumor volume and standardized uptake value in 18F-FDG PET. J Nucl Med. 2010;51:268–76.PubMedCrossRef Tylski P, Stute S, Grotus N, Doyeux K, Hapdey S, Gardin I, et al. Comparative assessment of methods for estimating tumor volume and standardized uptake value in 18F-FDG PET. J Nucl Med. 2010;51:268–76.PubMedCrossRef
21.
go back to reference Hristova I, Boellaard R, Vogel W, Mottaghy F, Marreaud S, Collette S, et al. Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. Eur J Nucl Med Mol Imaging. 2015;42:848–57.PubMedPubMedCentralCrossRef Hristova I, Boellaard R, Vogel W, Mottaghy F, Marreaud S, Collette S, et al. Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. Eur J Nucl Med Mol Imaging. 2015;42:848–57.PubMedPubMedCentralCrossRef
22.
go back to reference Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med. 2012;53:1041–7.PubMedPubMedCentralCrossRef Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med. 2012;53:1041–7.PubMedPubMedCentralCrossRef
23.
go back to reference Brendle C, Kupferschläger J, Nikolaou K, la Fougère C, Gatidis S, Pfannenberg C. Is the standard uptake value (SUV) appropriate for quantification in clinical PET imaging? - Variability induced by different SUV measurements and varying reconstruction methods. Eur J Radiol. 2015;84:158–62.PubMedCrossRef Brendle C, Kupferschläger J, Nikolaou K, la Fougère C, Gatidis S, Pfannenberg C. Is the standard uptake value (SUV) appropriate for quantification in clinical PET imaging? - Variability induced by different SUV measurements and varying reconstruction methods. Eur J Radiol. 2015;84:158–62.PubMedCrossRef
24.
go back to reference Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519–27.PubMed Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519–27.PubMed
25.
go back to reference Akamatsu G, Mitsumoto K, Taniguchi T, Tsutsui Y, Baba S, Sasaki M. Influences of point-spread function and time-of-flight reconstructions on standardized uptake value of lymph node metastases in FDG-PET. Eur J Radiol. 2014;83:226–30.PubMedCrossRef Akamatsu G, Mitsumoto K, Taniguchi T, Tsutsui Y, Baba S, Sasaki M. Influences of point-spread function and time-of-flight reconstructions on standardized uptake value of lymph node metastases in FDG-PET. Eur J Radiol. 2014;83:226–30.PubMedCrossRef
26.
go back to reference Akamatsu G, Ishikawa K, Mitsumoto K, Taniguchi T, Ohya N, Baba S, et al. Improvement in PET/CT image quality with a combination of Point-Spread Function and Time-of-Flight in relation to reconstruction parameters. J Nucl Med. 2012;53:1716–22.PubMedCrossRef Akamatsu G, Ishikawa K, Mitsumoto K, Taniguchi T, Ohya N, Baba S, et al. Improvement in PET/CT image quality with a combination of Point-Spread Function and Time-of-Flight in relation to reconstruction parameters. J Nucl Med. 2012;53:1716–22.PubMedCrossRef
27.
go back to reference Lasnon C, Hicks RJ, Beauregard JM, Milner A, Paciencia M, Guizard AV, et al. Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer. Clin Nucl Med. 2012;37:971–6.PubMedCrossRef Lasnon C, Hicks RJ, Beauregard JM, Milner A, Paciencia M, Guizard AV, et al. Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer. Clin Nucl Med. 2012;37:971–6.PubMedCrossRef
28.
go back to reference Barrington SF, MacKewn JE, Schleyer P, Marsden PK, Mikhaeel NG, Qian W, et al. Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG–PET data for clinical trials in lymphoma. Ann Oncol. 2011;22:739–45.PubMedCrossRef Barrington SF, MacKewn JE, Schleyer P, Marsden PK, Mikhaeel NG, Qian W, et al. Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG–PET data for clinical trials in lymphoma. Ann Oncol. 2011;22:739–45.PubMedCrossRef
Metadata
Title
Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis
Authors
Georg Kuhnert
Ronald Boellaard
Sergej Sterzer
Deniz Kahraman
Matthias Scheffler
Jürgen Wolf
Markus Dietlein
Alexander Drzezga
Carsten Kobe
Publication date
01-02-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3165-8

Other articles of this Issue 2/2016

European Journal of Nuclear Medicine and Molecular Imaging 2/2016 Go to the issue